| Molecule Name | Hetero Products | Therapy | Innovator Brand | Launch |
|---|---|---|---|---|
| Darbepoetin Alfa | Derise | Nephrology / Oncology | Aranesp (Amgen) | 2014 |
| Rituximab | Rilast | Oncology / Rheumatology | Mabthera/Rituxan (Roche) | 2015 |
| Bevacizumab | Bevaas | Oncology | Avastin (Roche) | 2016 |
| Adalimumab | Pamera | Autoimmune disorder | Humira (Abbvie) | 2017 |
| Trastuzumab | Sezuma | Oncology | Herceptin (Roche) | 2022 |
| PEG-Asparaginase | Pegalsa | Oncology | Oncaspar (Servier IP UK Ltd.) | 2023 |
| Tenecteplase | Tnkplase | Cardiology | Metalyse (Boehringer Ingelheim) | 2023 |
| L-Asparaginase | Aspalsa | Oncology | Elspar (Merck) | 2024 |
| Denosumab | Denotec | Oncology | Xgeva (Amgen) | 2025 |
| Molecule Name | Therapy | Innovator Brand | Current Stage |
|---|---|---|---|
| Pembrolizumab | Oncology | Keytruda (Merck) | Clinical Phase 3 Studies |
| Pertuzumab | Oncology | Perjeta (Genentech/Roche) | Clinical Phase 3 Studies |
| Nivolumab | Oncology | Opdivo (Bristol Myers Squibb) | Clinical Phase 3 initiation by Q4 2026 |
| Trastuzumab – Emtansine | Oncology | Kadcyla (Genentech/Roche) | Clinical Phase 3 initiation by Q1 2027 |
| Trastuzumab – Deruxtecan | Oncology | Enhertu (Daiichi Sankyo and AstraZeneca) | Clinical Phase 3 initiation by Q4 2027 |
| Daratumumab | Oncology | Darzalex (Janssen Biotech) | Early-stage Development |
| Brentuximab vedotin | Oncology | Adcetris (Takeda) | Early-stage Development |
| Sacituzumab Govitecan | Oncology | Trodelvy (Gilead Sciences) | Early-stage Development |
| Dupilumab | Oncology | Dupixent (Sanofi) | Early-stage Development |